Trent:₹3,256.10+30.96 (+0.96%)
Reliance Industries:₹1,377.50+1.93 (+0.14%)
Adani Ports:₹1,917.00-0.19 (-0.01%)
Tata Consumer:₹1,155.90+11.90 (+1.04%)
Titan Company:₹4,620.00-79.90 (-1.70%)
TCS:₹2,376.20+33.50 (+1.43%)
Trent:₹3,256.10+30.96 (+0.96%)
Reliance Industries:₹1,377.50+1.93 (+0.14%)
Adani Ports:₹1,917.00-0.19 (-0.01%)
Tata Consumer:₹1,155.90+11.90 (+1.04%)
Titan Company:₹4,620.00-79.90 (-1.70%)
TCS:₹2,376.20+33.50 (+1.43%)
Refer & Earn
Arihant Plus App

Arihant Plus App

Sudeep Pharma Ltd

Sudeep Pharma | 544619

Market Closed
₹1,191.50
₹20.61 (-1.70%)
As on 22/11/26, 3:48 PM
Market Cap13,690.5 CR
Current Price₹1,191.5
High / Low₹1,378 / 524.05
PE Ratio38.69
Book Value₹78.21
Dividend Yield0.00%
ROCE27.90%
ROE17.73%
Face Value₹2.00
Current Vol.1,14,421
Average Vol.---
ISININE0QPI01025
PB Ratio7.57
Debt to Equity0.21
Net Profit Margin27.14
Operating Margin39.14

SUDEEPPHRM - Share Price Chart

+₹0.00 (+0.00%)6M

Stock Performance

₹1,212.1₹1,190
₹1,191.5
Previous CloseToday's Open
₹524.05₹1,378
₹1,191.5
52W Low52W High
₹1,190Today's Open
₹1,212.1Previous Close
1,14,421Volume
₹524.0552W Low
₹1,37852W High

Ratios

No data available

About Company

  • Sudeep Pharma Limited was incorporated as Sudeep Pharma Private Limited' as a private limited company dated December 21, 1989, with the Registrar of Companies, Ahmedabad
  • Thereafter, Company was subsequently converted into a public limited company and the name of the Company was changed to Sudeep Pharma Limited' pursuant to fresh certificate of incorporation dated October 21, 2024, issued by the Central Processing Centre
  • The Company pioneered in India to introduce a product range of liposomal ingredients for nutrient absorption and stability
  • It operate 4 manufacturing facilities with 12 production lines in Vadodara, Gujarat with an annual installed capacity of 72,246 metric tons (MT)
  • Since the year 1989, Company has expanded business operations from production of excipients to a wide variety of over 100 products in the pharmaceutical, food and nutrition industries
  • Business is primarily structured into two verticals: Pharmaceutical, food and nutrition and Specialty ingredients
  • The Company focus on providing refined, mineral-based single ingredients essential to the pharmaceutical, food, and nutrition industries
  • These specialty ingredients play a key role in enhancing nutritional profiles, texture, and flavour across applications such as fortified dairy, beverages, and bakery products, as well as dietary supplements
  • Company came up with the IPO for issuing 15,092,749 Equity shares having the face value of Re 1 each, by raising aggregate funds of Rs 895 crore, which comprise a fresh issue of 1,602,023 Equity shares amounting to Rs 95 crore and the offer for sale of 13,490,726 Equity shares amounting to Rs 800 crore on November 25, 2025
  • The Company acquired 85% equity stake in Nutrition Supply and Services (Ireland) Limited (NSS), at Ireland making it a subsidiary in FY25

Research Calls

Research Calls
Locked Access

Explore all active research calls & maximize your profits

To access, login or signup with ArihantPlus

Technical Indicators

RSI56.49
SMA 201152.12
SMA 501130.00
SMA 1001062.91
SMA 200868.06
SMA 101202.77
MACD_12_26_Days31.00
EMA10Day1189.38
EMA20Day1162.54
EMA50Day1123.87
MACD_12_26_9_Days5.48
EMA100Day1051.93
EMA200Day888.56

Pivot Points

Volume Analysis

Delivery
Total Volume

Growth Rate

Revenue Growth27.94%
ROE25.37%
EBITDA Margin39.14%

All figures in ₹ Crores

Indicators20262025202420232022
Revenue
642.26
502.00
459.28
428.74
343.01
Interest
7.60
5.85
3.92
4.74
1.72
Expenses
420.36
312.05
277.62
339.62
275.55
Financing Profit
250.49
199.28
187.75
98.64
74.85
Financing Margin %
39%
40%
41%
23%
22%
Other Income
28.59
9.33
6.10
9.52
7.39
Depreciation
14.81
10.59
9.01
7.92
4.53
Profit before tax
228.07
182.85
174.82
85.98
68.60
Tax %
24%
24%
24%
28%
27%
Net Profit
174.28
138.73
133.19
62.32
50.17
EPS in Rs
15.50
12.79
12.28
5.74
356.01
Show % Change
ShareHolding
📊

No Information Available

No shareholding data available at this time.

DealDateTypeQuantityPriceTraded %
GOLDMAN SACHS FUNDS - GOLDMAN SACHS INDIA EQUITY PORTFOLIO04 Aug ‘26Purchase11,76,472₹850895.27%
NUVAMA CROSSOVER OPPORTUNITIES FUND - SERIES III04 Aug ‘26Sell6,14,112₹850467.33%
NUVAMA CROSSOVER OPPORTUNITIES FUND - SERIES IIIA04 Aug ‘26Sell5,62,360₹850427.94%
SBI MUTUAL FUND24 Jul ‘26Purchase20,00,000₹8001593.22%
NUVAMA CROSSOVER OPPORTUNITIES FUND - SERIES III24 Jul ‘26Sell10,60,000₹800844.41%
NUVAMA CROSSOVER OPPORTUNITIES FUND - SERIES IIIA24 Jul ‘26Sell9,40,000₹800748.81%

News

📊

No Information Available

No news available for this company.
Record Date
Corporate Action
Information
Announcement Day
04 Aug 2026
AGM
AGM
10 Jul 2026
23 Jul 2026
Final Dividend (₹1.5)
The Board has recommended a Final Dividend of Rs. 1.50/- (150%) per Equity share of Rs. 1/- each for the year ended 31st March 2026 subject to approval of shareholders in the forthcoming Annual General Meeting
21 May 2026

Peers

LTP(₹)
Market Cap(₹ Cr.)
P/E Ratio(Ratio)
P/B Ratio(Ratio)
Cash Earnings(Ratio)
Debt to Equity(Ratio)
Net Profit Ratio(%)
1,192
13,467
72
14
66
0
27.14%
1,618
1,64,779
61
15
54
0
16.92%
2,509
74,376
31
5
23
0
11.62%
6,566
55,998
113
13
75
0
21.69%
4,933
54,185
79
6
50
0
11.48%
10,150
52,084
57
12
48
0
20.02%
1,089
36,683
24
3
18
4
9.63%
561
28,304
33
6
30
0
16.20%
1,620
21,507
85
8
65
0
18.92%
1,530
20,870
19
3
16
0
6.98%
Showing 10 of 134 Results

Frequently Asked Questions

What is Share Price of Sudeep Pharma Ltd?

The current share price of Sudeep Pharma Ltd (Sudeep Pharma) is ₹1191.50. This price reflects the latest market valuation and is updated in real-time during trading hours.

What is the P/E Ratio of Sudeep Pharma Ltd?

The Price-to-Earnings (P/E) ratio of Sudeep Pharma Ltd is 72.69. This indicates how much investors are willing to pay per rupee of earnings, helping assess if the stock is overvalued or undervalued.

What is the 52-week high and low of Sudeep Pharma Ltd?

Sudeep Pharma Ltd has a 52-week high of ₹1378.00 and a 52-week low of ₹524.05. This range shows the stock's price volatility over the past year.

What is the Dividend Yield of Sudeep Pharma Ltd?

Sudeep Pharma Ltd offers a dividend yield of 0.00%. This represents the annual dividend payment as a percentage of the current stock price, indicating the income return for investors.

What is the EPS of Sudeep Pharma Ltd?

The Earnings Per Share (EPS) of Sudeep Pharma Ltd is ₹16.67. EPS indicates the company's profitability on a per-share basis and is a key metric for evaluating financial performance.

What is the ROE of Sudeep Pharma Ltd?

Sudeep Pharma Ltd has a Return on Equity (ROE) of 17.73%. ROE measures how effectively the company uses shareholders' equity to generate profits, with higher values generally indicating better performance.

Disclaimer:

Please note that the above list and information is for research purposes only and are not recommendations. Do your own due diligence or consult an investment advisor before investing. The above data is dynamic in nature and subject to real-time changes and is derived from CMOTS.

mobile

Ready to invest smarter?
Download the app today.

GET IT ON

GET IT ON

Google Play

4.5

DOWNLOAD ON THE

DOWNLOAD ON THE

App Store

4.2